f20061603

\"The challenge is most people present when it\'s very late stage, and it\'s about managing symptoms as opposed to curing them. So the key thing that you can do is detect the disease early.And that is what we think the breathe alive technology allows for picking it up with the early stage when it's still treatable. for\" The testing of the Owlstone breathalyzer is currently limited to patients with suspected esophageal and stomach cancers. Esophageal cancer is a leading cause of cancer deaths around the world. Most cases are reported in developing countries. Esophageal cancer in its early stages usually has no signs. However, the chemical markers of the disease are present even in the earliest stage. Over the two-year trial, researchers will extend testing of the breathalyzer to include patients with other cancers.